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Abstract 
Background: In ICU patients, digestive tract colonization by multidrug-resistant (MDR) Gram-negative (G−) bac-
teria is a significant risk factor for the development of infections. In patients undergoing extracorporeal membrane 
oxygenation (ECMO), colonization by MDR bacteria and risk of subsequent nosocomial infections (NIs) have not been 
studied yet. The aim of this study is to evaluate the incidence, etiology, risk factors, impact on outcome of gastrointes-
tinal colonization by MDR G− bacteria, and risk of subsequent infections in patients undergoing ECMO.
Methods: This is a retrospective analysis of prospectively collected data: 105 consecutive patients, treated with 
ECMO, were admitted to the ICU of an Italian tertiary referral center (San Gerardo Hospital, Monza, Italy) from Janu-
ary 2010 to November 2015. Rectal swabs for MDR G− bacteria were cultured at admission and twice a week. Only 
colonization and NIs by MDR G− bacteria were analyzed.
Results: Ninety-one included patients [48.5 (37–56) years old, 63% male, simplified acute physiology score II 37 (32–
47)] underwent peripheral ECMO (87% veno-venous) for medical indications (79% ARDS). Nineteen (21%) patients 
were colonized by MDR G− bacteria. Male gender (OR 4.03, p = 0.029) and duration of mechanical ventilation (MV) 
before ECMO > 3 days (OR 3.57, p = 0.014) were associated with increased risk of colonization. Colonized patients had 
increased odds of infections by the colonizing germs (84% vs. 29%, p < 0.001, OR 12.9), longer ICU length of stay (LOS) 
(43 vs. 24 days, p = 0.002), MV (50 vs. 22 days, p < 0.001) and ECMO (28 vs. 12 days, p < 0.001), but did not have higher 
risk of death (survival rate 58% vs. 67%, p = 0.480, OR 0.68). Infected patients had almost halved ICU survival (46% vs. 
78%, p < 0.001, OR 4.11).
Conclusions: In patients undergoing ECMO for respiratory and/or circulatory failure, colonization by MDR G− bac-
teria is frequent and associated with more the tenfold odds for subsequent infection. Those infections are associated 
with an increased risk of death.
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Background
Extracorporeal membrane oxygenation (ECMO) is a 
life-support technique used in patients with potentially 
reversible refractory respiratory or circulatory failure [1]. 
Healthcare-associated infections (HAIs) are common in 
ECMO patients [2–4] due to several predisposing fac-
tors: intensive care unit (ICU) hospitalization, patients’ 
comorbidities, immunodeficiency induced by the critical 
illness and invasiveness of ECMO and other life-support 
procedures (e.g., invasive mechanical ventilation, renal 
replacement therapies). ECMO patients suffering from 
HAIs have longer ECMO runs, ICU length of stay (LOS), 
and higher mortality rate [3]. Recently, we reported that 
HAIs during ECMO are frequently caused by multidrug-
resistant (MDR) Gram-negative (G−) bacteria [2], and 
we observed that patients infected by MDR bacteria had 
higher odds for death.
ICU patients have higher rates of digestive tract 
colonization by MDR G− bacteria (i.e., producing 
extended-spectrum β-lactamase (ESBL+) and carbape-
nem-resistant bacteria) compared to patients admitted to 
general wards [5, 6]. Such colonizations could represent a 
significant risk factor for the development of subsequent 
infections [7–9]. A growing body of evidence indicates 
that dysbiosis of the gut microbiota is common in criti-
cally ill patients and may play a crucial role in increasing 
the risk of gastrointestinal colonization. To our knowl-
edge, the rate of colonization by MRD bacteria and the 
risk of subsequent infections have not been studied in 
ECMO patients. In such a fragile population, prevention, 
early diagnosis and prompt treatment of MDR HAIs may 
significantly affect morbidity and mortality.
The aim of the present study is to evaluate the inci-
dence, risk factors, and impact on subsequent HAIs as 
well as clinical outcomes of digestive tract colonization 
by MDR G− bacteria in a large cohort of non-surgical 
patients undergoing ECMO for respiratory or circulatory 
failure.
Methods
We present a retrospective analysis of prospectively 
collected data of all consecutive ECMO patients admit-
ted to the General Intensive Care Unit (ICU) of San 
Gerardo Hospital (Monza, Italy) from January 2010 
to November 2015. For further details on ECMO set-
ting and patient care see Setting and Standard of Care, 
Additional file 1: Methods S1. Notably, at San Gerardo 
Hospital ICU, rectal swabs are collected and cultured 
for ESBL+ (i.e., E. coli, Enterobacter spp.) and carbap-
enem-resistant (i.e., Acinetobacter spp., P. aeruginosa, 
K. pneumoniae carbapenemase producing and other 
Enterobacteriaceae) G− bacteria at ICU admission and 
twice a week. We will refer to ESBL+ and carbapenem-
resistant G− bacteria as “MDR G− bacteria”.
The Institutional Ethical Committee, and written 
informed consent was waived due to the retrospective 
observational design of the study. All patients receiving 
ECMO support were considered for inclusion. Exclu-
sion criteria were: (1) ICU length of stay (LOS) < 24 h; (2) 
ECMO use < 24 h; (3) occurrence of a NI prior to ECMO 
connection; (4) missing medical records. At baseline, the 
following patients data and ECMO parameters were col-
lected: demographics (i.e., gender, age); comorbidities 
[10]; immunocompromised status (i.e., chronic immuno-
suppressive therapies, active hematological malignancies, 
autoimmune diseases); diagnosis at admission; infections 
at admission; renal replacement therapy before ECMO 
cannulation; severity scores (i.e., Sequential Organ Fail-
ure Assessment—SOFA—score and Simplified Acute 
Physiology Score II—SAPS II of the first 24  h of ICU 
stay);  PaO2/FiO2 at ECMO connection; ECMO configu-
ration (i.e., veno-venous, veno-arterial, other); transfer 
from peripheral hospital; length of invasive mechanical 
ventilation (IMV) before ECMO connection; antimicro-
bial therapy (i.e., exposure to extended-spectrum penicil-
lins with β-lactamase inhibitor or carbapenems).
The following outcomes were recorded: survival at 
ICU discharge, ICU LOS, duration of IMV, and dura-
tion of ECMO.
All the positive microbial cultures obtained from ICU 
admission until ICU dismissal have been independently 
evaluated in light of the available clinical, laboratory, and 
radiographic data by two specialized intensivists (VS and 
GG) and two infectious diseases specialists (AB and LA) 
following international guidelines [11–13]. The patients 
with rectal or perineal swabs positive for MDR G− bac-
teria were considered “colonized”. Similarly, patients with 
diagnostic criteria for ventilator-associated pneumonia 
(VAP), catheter-associated urinary tract infection (UTI), 
bloodstream infection (BSI), catheter-related blood-
stream infection (CRBSI) (see Additional file 1: Table S1, 
Methods S1) [9] due to MDR G− bacteria were consid-
ered “infected”. Infections due to pathogens different 
from MDR G− bacteria were not considered in this anal-
ysis and have been described elsewhere [2].
Keywords: Retrospective study, Health care-associated infection, Extracorporeal membrane oxygenation, Multi-drug 
resistance, Colonization
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Statistical analysis
Due to the retrospective nature of the study, no statistical 
power calculation was performed a priori, and the sam-
ple size was equal to the number of patients treated dur-
ing the recruitment period. Data are presented as median 
and interquartile range (IQR) for continuous variables. 
Categorical variables are expressed as number of patients 
(percentage of the subgroups). For binary outcome 
measures, odds ratios (OR) and associated 95% likeli-
hood ratio-based confidence intervals were calculated, 
and the comparison between patients’ populations (i.e., 
colonized vs. non-colonized, infected vs. non-infected) 
were performed with Chi-square test or Fisher’s test, 
as appropriate. The Kruskal–Wallis test was utilized to 
compare non-parametric continuous variables between 
patients’ populations. Kaplan–Meier survival curve anal-
ysis was used with log-rank test for comparison of colo-
nization-free and infection-free rates. Observations were 
right-censored.
Univariate regression models were applied to identify 
risk factors associated with colonization and infection. 
All subjects were included in the models, and follow-up 
began at the time of ECMO initiation. All statistical tests 
were 2-tailed, and statistical significance was accepted 
at p < 0.05. Analyses were performed using JMP 12.1 Pro 
(SAS, Cary, NC, USA) statistical program.
Results
From January 2010 to November 2015, 105 patients 
were treated with ECMO at the General Intensive Care 
Unit (ICU) of San Gerardo Hospital (Monza, Italy). 
Ninety-one subjects (median age 49  years; 63% male) 
were included in the analysis. Reasons for exclusion of 
the remaining patients were: diagnosis of HAI prior to 
ECMO connection (10 patients), age < 18  years (2 sub-
jects), ICU LOS and ECMO shorter than 24 h (2 patients) 
(see Additional file 1: Figure S1, Results).
Patients’ characteristics, comorbidities, and indications 
for ECMO support are summarized in Table 1, and Addi-
tional file 1: Table S2.
We analyzed a total of 1213 positive cultures. Nine-
teen (21%) patients were colonized by MDR G− bacte-
ria. Of them, 11 (58%) were colonized by A. baumannii, 
4 (21%) by K. pneumoniae, 2 (11%) by P. aeruginosa, and 
2 (10%) by other Enterobacteriaceae. The clinical char-
acteristics of colonized and non-colonized patients are 
depicted in Table  2. Factors associated with increased 
risk for colonization were male gender [OR 4.03 (1.08–
15.0), p = 0.029] and duration of IMV before ECMO 
connection > 3  days [OR 3.57 (1.25–10.2), p = 0.014]. 
Among the other variables, ARDS and use of RRT 
prior to ECMO connection were associated with high, 
but not significant, OR estimates [i.e., 6.00 (0.74–48.2) 
and 1.48 (0.41–5.29), respectively]. Multivariable logis-
tic regression was not deemed appropriate due to the 
small number of events (i.e., n = 19).
Colonization was diagnosed after a median interval of 
13 (1–22), 16 (8–32) and 17 (10–34) days from ECMO 
connection, institution of IMV, and hospital admission, 
respectively. Of note, 5 (26%) of the colonization were 
diagnosed in the first three days after ICU admission. 
The time course of colonization is depicted in Fig. 1.
Colonized patients had significantly longer ICU LOS 
[i.e., 43 (23–84) vs. 24 (12–37), p = 0.002], longer IMV 
[i.e., 50 (23–89) vs. 22 (10–37) days, p < 0.001] and 
longer ECMO support [i.e., 28 (16–60) vs. 12 (6–24), 
p < 0.001]. Colonization also increased the risk of need 
for tracheostomy [i.e., 68% vs. 28%, p < 0.001, OR 5.63 
(1.88–16.8)]. In our cohort colonized patients did not 
have a higher risk of death than not colonized patients 
[survival rate 58% vs. 67%, p = 0.480, OR 0.68 (0.24–
1.93)], but they had more than tenfold odds of develop-
ing an infection caused by the colonizing germs [84% 
vs. 29%, p < 0.001, OR 12.9 (3.41–49.1)] with high sen-
sitivity [0.432 (95% CI 0.287–0.591)] and specificity 
[0.944 (95% CI 0.849–0.981)] of prior colonization to 
predict subsequent MDR G− bacterial infection.
In colonized patients, we observed 13 VAP, 2 UTI, 
and 1 CRBSI at a median of 11 (4–22) days from the 
day of diagnosis of colonization and 24 (13–60), 33 
(19–47) and 34 (20–64) days from ECMO connection, 
intubation and hospital admission, respectively.
Overall, 37/91 patients (41%) developed an infection 
due to MDR G− bacteria (see Additional file 1: Figure 
S2, Tables S3, S4), which occurred at a median of 16 
(7–31), 22 (12–45) and 25 (15–40) days from ECMO 
connection, intubation and hospital admission. The 
most common infection was VAP due to A. baumannii, 
both in the colonized (n = 7/16 infected patients, 44%) 
and non-colonized (n = 5/21 infected patients, 25%).
The clinical characteristics of infected and non-
infected patients are depicted in Table 3. Factors associ-
ated with increased risk for infection were male gender 
[OR 2.68 (1.09–7.00), p = 0.030], duration of IMV before 
ECMO connection > 3  days [OR 7.33 (2.86–20.3), 
p = 0.001], use of RRT prior to ECMO connection [OR 
5.29 (1.63–20.6), p = 0.001], diagnosis of ARDS [OR 8.04 
(2.09–53.0), p = 0.001], infection at admission [OR 3.28 
(1.22–9.93), p = 0.017] and colonization [OR 12.9 (3.83–
59.9, p = 0.001]. Kaplan–Meier survival curve analysis 
with log-rank test showed a significant difference in the 
time course of infection between colonized and non-
colonized patients (p = 0.025), indicating that infections 
developed earlier in colonized patients (Fig. 2).
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Infected patients had longer ECMO support [i.e., 27 
(14–61) vs. 10 (5–16), p < 0.001], longer IMV [i.e., 44 
(25–87) vs. 18 (9–31), p < 0.001] and longer ICU LOS 
[i.e., 43 (25–83) vs. 19 (10–29), p < 0.001]. Moreover, 
infected patients had increased needs for RRT [i.e., 22 
(59%) vs. 11 (20%), p < 0.001, OR 5.73 (2.31–15.6)] and 
tracheostomy [i.e., 18 (49%) vs. 15 (28%), p = 0.042, 
OR 2.46 (1.03–6.01)]. Finally, infected patients had 
almost halved ICU survival [i.e., 17 (46%) vs. 42 (78%), 
p < 0.001, OR 4.11 (1.68–10.5)].
The time course of antibiotic use is shown in Addi-
tional file 1: Table S5. β-Lactam/β-lactamase inhibitors 
and antipseudomonal carbapenems were the most com-
monly employed antibiotic classes at time of perineal 
and rectal swab collection, while antipseudomonal car-
bapenems and colistin were the most common classes 
Table 1 Patients’ and treatment characteristics at the ECMO connection (n = 91)
Data are presented as absolute frequency (% of the included patients) or as median and interquartile range
ECMO extracorporeal membrane oxygenation, COPD chronic obstructive pulmonary disease, ARDS acute respiratory distress syndrome, SAPS II simplified acute 
physiology score, SOFA sequential organ failure assessment, ECCO2R extracorporeal carbon dioxide removal, AIDS acquired immunodeficiency syndrome, IMV invasive 
mechanical ventilation, RRT renal replacement therapy
a Including high-dosage corticosteroids, immunosuppressants or both
Patients’ characteristics Subgroups Frequency or median
Age (years) 48.5 (37–56)
Gender (male) 58 (63%)
Weight (kg) 70 (65–85)
Charlson Comorbidity Index 1 (0–3)
Major comorbidities Active smoker 26 (28%)
Immunomodulating  therapiesa 22 (24%)
Hematologic malignancies 13 (14%)
COPD 10 (11%)
Hepatopathy 10 (11%)
Coronary artery disease 9 (10%)
Diabetes 7 (8%)
AIDS 3 (3%)
Transferred from peripheral hospital 76 (82%)
Transferred while on ECMO support 58 (63%)
Diagnosis and admission ARDS 72 (78%)
Cardiogenic shock 6 (7%)
Asthma 4 (4%)
COPD exacerbation 4 (4%)
Septic shock 4 (4%)
Other 2 (2%)
Infection at admission 65 (71%)
Autoimmune disease 8 (9%)
SAPS II 37 (32–47)
SOFA score 8 (6–11)
PaO2/FiO2 < 100 mmHg 70 (76%)
ECMO duration (days) 14 (8–27)
Veno-venous ECMO 80 (87%)
Low flow  ECCO2R 8 (9%)
Femo-femoral cannulation 76 (83%)
ECMO circuits 2 (1–4)
IMV duration (days) 25 (12–44)
IMV duration prior to ECMO connection (days) 2 (1–6)
RRT during ECMO course 33 (36%)
RRT prior to ECMO connection 15 (16%)
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Table 2 Univariable logistic regression analyzing risk factor for colonization due to multidrug-resistant Gram-negative 
bacteria
Data are presented as absolute frequency (% of the included patients) or as median and interquartile range
IMV invasive mechanical ventilation, ECMO extracorporeal membrane oxygenation, RRT renal replacement therapy, SOFA sequential organ failure assessment, SAPS II 
simplified acute physiology score, ARDS acute respiratory distress syndrome
a Odds ratio of continuous variables are odds ratio per unit increase in variable
b Including high-dosage corticosteroids, immunosuppressants or both. Statistically significant results are highlighted in italic
Clinical characteristics Colonized (n = 19) Non-colonized 
(n = 72)
p Odds  ratioa (95% CI)
Year
 2010 4 (21%) 9 (13%) 0.597
 2011 1 (5%) 13 (18%)
 2012 3 (16%) 10 (14%)
 2013 2 (11%) 13 (18%)
 2014 4 (21%) 15 (21%)
 2015 5 (26%) 12 (17%)
Age (years) 52 (39–64) 46 (34–55) 0.075 1.03 (0.99–1.07)
Gender (male) 16 (84%) 41 (57%) 0.029 4.03 (1.08–15.0)
Charlson Comorbidity Index 2 (1–4) 1 (0–3) 0.408 1.08 (0.88–1.31)
Transferred from peripheral hospital 15 (79%) 60 (83%) 0.655 0.75 (0.21–2.65)
IMV > 3 days prior to ECMO connection 11 (58%) 20 (28%) 0.014 3.57 (1.25–10.2)
RRT prior to ECMO connection 4 (21%) 11 (15%) 0.546 1.48 (0.41–5.29)
SOFA score 8 (6–11) 8 (6–11) 0.657 0.97 (0.84–1.10)
SAPS II 39 (32–53) 36 (32–46) 0.469 1.01 (0.97–1.05)
ARDS 18 (95%) 54 (75%) 0.059 6.00 (0.74–48.2)
PaO2/FiO2 < 100 mmHg 16 (84%) 54 (75%) 0.397 1.77 (0.46–6.81)
Infection at admission 15 (79%) 49 (68%) 0.355 1.76 (0.52–5.89)
Chronic  immunosuppressionb 4 (21%) 16 (22%) 0.912 0.93 (0.27–3.20)
Veno-venous support 16 (84%) 63 (88%) 0.706 0.76 (0.18–3.14)
Exposure to piperacillin/tazobactam 8 (42%) 40 (56%) 0.296 0.58 (0.21–1.62)
Exposure to carbapenems 10 (53%) 39 (54%) 0.905 0.94 (0.34–2.58)
Fig. 1 Probability of being colonization-free. Kaplan–Meier estimates 
of the unadjusted cumulative probability of being colonization-free 
(tracked line). Tick marks represent censored patients
Fig. 2 Probability of being infection-free. Kaplan–Meier estimates 
of the unadjusted cumulative probability of being infection-free. 
Tracked line represent colonized patients, tick line represent 
non-colonized patients. Tick marks represent censored patients
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of antibiotics introduced as empiric and cultured-tar-
geted therapy.
Discussion
In the present study, we analyzed the epidemiology of 
digestive tract colonization by MDR G− bacteria in a 
large cohort of non-surgical patients undergoing ECMO 
for respiratory or circulatory failure. MDR G− bacteria 
colonization was highly frequent (21% of the patients), 
and risk factors associated with colonization were male 
sex and the need for prolonged (i.e., > 3 days) IMV prior 
to ECMO connection. Colonized patients had more than 
tenfold odds for subsequent infection by MDR G− bacte-
ria, and those infections (mainly VAP due to A. bauman-
nii) were associated with an increased risk of death [14].
In a previous analysis [2], we observed that up to 55% of 
ECMO patients develop at least an infectious complica-
tion, which is associated with worse clinical outcomes. Of 
those infections, 56% were caused by MDR bacteria, par-
ticularly non-fermenting G− bacteria. At San Gerardo 
Hospital general ICU, rectal swabs are routinely collected 
and cultured for MDR G− bacteria at ICU admission and 
twice a week. We hypothesized that, in patients under-
going ECMO, digestive tract colonization might precede 
infection and thus we retrospectively evaluated such cul-
tures and their relationship with subsequent infections. 
To our knowledge, this is the first study evaluating the 
relationship between multidrug resistant bacteria gut 
colonization and infections in a relatively large cohort of 
ECMO patients.
Recent studies performed in European ICUs [15, 16], 
described colonization by MDR G− pathogens to occur 
in 2–10% of the patients. The higher rate of colonization 
documented in our patient population may be explained 
by several factors. First, in the last decade, Mediterra-
nean countries and Italy, in particular, have been plagued 
by an epidemic of MDR bacteria in hospitalized patients 
and even in the general population [17, 18], with ESBL+ 
colonization reaching up to 50% of the patients [19]. Sec-
ond, the high rate of colonization may reflect the inva-
siveness of treatment [20, 21] of our patients. Indeed, all 
our patients were invasively ventilated, and up to 50% 
underwent CRRT. We observed that longer duration of 
IMV prior to ECMO and male gender were associated 
Table 3 Univariable logistic regression analyzing risk factor for  infection due to  multidrug-resistant Gram-negative 
bacteria
Data are presented as absolute frequency (% of the included patients) or as median and interquartile range
IMV invasive mechanical ventilation, ECMO extracorporeal membrane oxygenation, RRT renal replacement therapy, SOFA sequential organ failure assessment, SAPS II 
simplified acute physiology score, ARDS acute respiratory distress syndrome, ICU intensive care unit, LOS length of stay
a Odds ratio of continuous variables are odds ratio per unit increase in variable
b Including high-dosage corticosteroids, immunosuppressants or both. Statistically significant results are highlighted in italic
Clinical characteristics Infected (n = 37) Non-infected (n = 54) p Odds  ratioa (95% CI)
Year
 2010 5 (14%) 8 (15%) 0.970
 2011 6 (16%) 8 (15%)
 2012 4 (11%) 9 (17%)
 2013 6 (16%) 9 (17%)
 2014 8 (22%) 11 (20%)
 2015 8 (22%) 9 (17%)
Age (years) 50 (37–55) 47 (36–58) 0.587 1.00 (0.98–1.03)
Gender (male) 28 (76%) 29 (54%) 0.030 2.68 (1.09–7.00)
Charlson Comorbidity Index 1 (0–3) 1 (0–3) 0.839 1.21 (0.17–7.82)
Transferred from peripheral hospital 32 (86%) 43 (80%) 0.393 1.63 (0.53–5.62)
IMV > 3 days prior to ECMO connection 22 (59%) 9 (17%) 0.001 7.33 (2.86–20.3)
RRT prior to ECMO connection 11 (30%) 4 (7%) 0.005 5.29 (1.63–20.6)
SOFA 8 (6–12) 8 (6–11) 0.348 1.05 (0.94–1.17)
SAPS II 38 (32–49) 37 (30–43) 0.806 1.00 (0.97–1.03)
ARDS 35 (95%) 37 (69%) 0.001 8.04 (2.09–53.0)
PaO2/FiO2 < 100 mmHg 32 (86%) 38 (70%) 0.066 2.69 (0.93–8.97)
Infection at admission 31 (84%) 33 (61%) 0.017 3.28 (1.22–9.93)
Chronic  immunosuppressionb 8 (78%) 12 (78%) 0.946 0.96 (0.34–2.63)
Veno-venous support 34 (92%) 45 (83%) 0.223 2.26 (0.62–10.8)
Colonization 16 (43%) 3 (6%) 0.001 12.9 (3.83–59.9)
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with increased risk of colonization, while the use of RRT 
before ECMO cannulation had elevated though non-
significant odds ratios for colonization. Third, ECMO 
patients usually receive broad-spectrum antimicrobi-
als, which increase the risk of selection of MDR germs 
[9, 22]. Contrary to previous literature [23, 24], in our 
patients’ cohort exposure to carbapenems and extended-
spectrum β-lactams/β-lactamase inhibitors and sever-
ity of illness (SOFA, SAPS II and  PaO2/FiO2 ratio) were 
not associated with an increased risk of colonization by 
G− MDR bacteria. Finally, both invasiveness of care [21] 
and critical illness itself [25] alter the patients’ microbi-
ota (i.e., lower diversity, lower abundance of commensals 
genera, overgrowth by single genera), limiting the protec-
tive role of microbiome thus increasing susceptibility to 
infection [26].
As previously documented [8, 9, 27], colonization by 
MDR G− bacteria was independently associated with 
increased odds for subsequent infection from the colo-
nizing bacteria. While colonization per se was not associ-
ated with an increased risk of death, colonized patients 
had increased length of mechanical ventilation and ICU 
stay. In addition, infected patients had more than four-
fold odds of death as compared to non-infected patients. 
In our opinion, the finding that infection but not colo-
nization is associated with an increased risk of death is 
of utmost clinical interest. Treatment of bacterial colo-
nization with broad-spectrum antibiotics is not rec-
ommended in patients with critical illness-associated 
immune dysfunction since it usually does not achieve the 
eradication of colonizing germs, while it instead increases 
evolutionary pressure towards the selection of multidrug 
resistant bacteria [28, 29]. Contrarily, management of 
colonization should aim at (1) early recognizing coloni-
zation through active screening protocols and molecular 
biology techniques [30]; (2) limiting the spread of MDR 
bacteria (by enforcing hand hygiene, contact precautions 
and cohort isolation [31]), and ideally, (3) avoiding devel-
opment of infection in colonized patients; (4) institute 
patient-specific antibiotic therapy when a new infection 
would develop [28]. To reach the latest goal, immuno-
logic profiling [32] of patients at highest risk for progres-
sion from colonization to infection would be crucial, also 
to guide the eventual institution of immunomodulating 
treatments. Also, we believe that gut microbiota may be 
a relevant therapeutic target for specific interventions 
(such as probiotics administration, decolonization strat-
egies, etc.) that might contribute to reducing the risk of 
digestive tract colonization by MDR bacteria. Further 
prospective observational studies are needed to evaluate 
such aspects.
In our patient cohort, colonization by MDR G− bac-
teria occurred in patients with longer ICU stay, longer 
IMV and higher invasiveness of care, but was not associ-
ated with an increased risk of death. As such, coloniza-
tion may be considered as a proxy for a more complicated 
clinical course, rather than a causative determinant of the 
unfavorable clinical course.
The main limitation of our study is its retrospective and 
single-center nature, which precludes the generalization 
of the results to the overall population of medical ECMO 
patients. Moreover, colonization due to MDR G+ bacte-
ria (namely methicillin-resistant Staphylococcus aureus) 
was not evaluated since routine surveillance for MRSA 
colonization is not performed at San Gerardo Hospi-
tal General ICU due to the limited incidence of such 
infection. Finally, since around 25% of the colonizations 
occurred in the first 3 days from ICU admission, in this 
specific subgroup, we cannot clearly distinguish between 
community-acquired and hospital-acquired colonization, 
as most of our patients were admitted from peripheral 
hospitals, where surveillance was rarely performed.
Conclusions
In a large cohort of non-surgical patients undergoing 
ECMO for respiratory and/or circulatory failure, colo-
nization by MDR G− bacteria was frequent, associated 
with male sex and with prolonged duration (i.e., > 3 days) 
of IMV prior to ECMO connection. Colonized patients 
had more than tenfold odds for subsequent infection by 
MDR G− bacteria, and those infections were associated 
with an increased risk of death.
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